Pharmacodynamic study of 131I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer

The aim of the present study was to explore the inhibitory effect of 131I-labeled ovarian cancer antigen 215 (131I-CA215) antibody on human OC-3-VGH ovarian cancer. A subcutaneous transplanted tumor model of estrogen‑resistant human OC‑3‑VGH ovarian cancer in nude mice was established. The model mice were randomly divided into seven groups, which were the negative control (NC), positive control (PC; 60 mg/kg cyclophosphamide), high‑dose CA215 antibody (HA; 10 mg/kg), low‑dose CA215 antibody (LA; 2 mg/kg), high‑dose 131I‑CA215 antibody (131I‑HA; 10 mg/kg + 125 µCi), medium‑dose 131I‑CA215 antibody (131I‑MA; 6 mg/kg + 75 µCi) and low‑dose 131I‑CA215 antibody (131I‑LA; 2 mg/kg + 25 µCi) groups. Each group received intraperitoneal administration for 14 consecutive days. At 24 h after the final administration, the tumor was removed and weighed to calculate the tumor inhibition rate (TIR) and the relative tumor increase rate (T/C). Compared with the NC group, the HA group, as well as the 31I‑HA and 131I‑MA antibody groups, exhibited significantly inhibited tumor growth. The relative T/C values were 54, 30 and 48%, respectively, and the TIRs were 33.59, 64.89 and 45.80%, respectively. All differences were statistically significant. The difference between the HA and 131I‑HA groups also presented statistical significance. CA215 and 131I‑CA215 antibodies can markedly inhibit OC‑3‑VGH ovarian cancer. The high‑dose 131I‑CA215 antibody demonstrated a clear synergetic effect.